Can 0.025-inch Guidewire VisiGlideTM become a Standard in the ERCP-related Procedures : VIP Study.
Br J Med Med Res
;
2014 Apr; 4(12): 2418-2430
Article
in English
| IMSEAR
| ID: sea-175182
ABSTRACT
Aims:
With the progress of development of 0.025-inch guidewire (GW), various treatments with 0.025-inch GW have become possible. To date, however, there has been no multicenter cooperative prospective study using 0.025-inch GW VisiGlideTM as the versatile GW. This time, we decided to examine the result of the use of 0.025-inch GW VisiGlideTM as the first choice in the endoscopic retrograde cholangiopancreatography (ERCP)-related procedure without selecting the patient in a multicenter cooperative prospective study. StudyDesign:
Multi-center single arm prospective study.Methodology:
The 0.025-inch GW VisiGlideTM was used in the patients with biliopancreatic diseases requiring ERCP as the first choice to examine the accomplishment rate of procedure and the incidence of accidental symptom.Results:
The accomplishment rate of procedure was 92.8% (180/194). The accidental symptoms of ERCP-related procedures were observed at 4.6% (9/194) and GW perforation was observed as a GW-related accidental symptom at 2.1% (4/194) but all the accidental symptoms resolved conservatively.Conclusion:
The 0.025-inch GW VisiGlideTM has a high accomplishment rate of procedure and a low incidence of accidental symptom in its use in the ERCP-related procedure, and it was suggested that it may be available as a versatile GW. Clinical Trial Registry (UMIN000008180).
Full text:
Available
Index:
IMSEAR (South-East Asia)
Type of study:
Controlled clinical trial
/
Observational study
Language:
English
Journal:
Br J Med Med Res
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS